US FDA Rebates Biosimilar Fees, Limits Generic Fee Hike In FY 2022

 
• By Derrick Gingery
Fees up and down
Many generic and outsourcer user fees will increase in FY 2022, while biosimilar fees will remain steady or decrease. • Source: Alamy

More from Biosimilars

More from Biosimilars & Generics